Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin

Cardiovascular Drugs and Therapy

Volumn 24, Issue 1, 2010, Pages 41-47

  Cay, Serkan ^a,f   Cagirci, Goksel ^b   Sen, Nihat ^c   Balbay, Yucel ^a   Durmaz, Tahir ^d   Aydogdu, Sinan ^a,e  

^a Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c MUSTAFA KEMAL UNIVERSITY   (Turkey)

^d ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f NONE   (Turkey)

Author keywords

Infarction; Necrosis; Rosuvastatin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN; ROSUVASTATIN; TIROFIBAN; TROPONIN I;

AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; TROPONIN I;

EID: 77951295359     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6224-1     Document Type: Article

References (23)

1. K Thygesen JS Alpert HD White 2007 Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction J Am Coll Cardiol 50 2173 2195 10.1016/j.jacc.2007.09.011 18036459 (Pubitemid 350123680)
2. AH Wu WE Boden RG McKay 2002 Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention Am J Cardiol 89 1300 1302 10.1016/S0002-9149(02)02331-7 1:CAS:528:DC%2BD38XjvVShsLY%3D 12031733 (Pubitemid 34606894)
3. MJ Ricciardi CJ Davidson G Gubernikoff, et al. 2003 Troponin I elevation and cardiac events after percutaneous coronary intervention Am Heart J 145 522 528 10.1067/mhj.2003.2 1:CAS:528:DC%2BD3sXisFSgtL4%3D 12660677 (Pubitemid 36390500)
4. BE Tardiff RM Califf JE Tcheng, et al. 1999 Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II J Am Coll Cardiol 33 88 96 10.1016/S0735-1097(98)00551-8 1:STN:280:DyaK1M7jtFOisQ%3D%3D 9935014 (Pubitemid 29064078)
5. TQ Kong CJ Davidson SN Meyers, et al. 1997 Prognostic implication of creatine kinase elevation following elective coronary artery interventions JAMA 277 461 466 10.1001/jama.277.6.461 1:STN:280:DyaK2s7nt1Wrtw%3D%3D 9020269
6. AE Abdelmeguid EJ Topol PL Whitlow, et al. 1996 Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions Circulation 94 1528 1536 1:STN:280:DyaK28vjvVCmsg%3D%3D 8840840
7. AE Abdelmeguid SG Ellis SK Sapp, et al. 1996 Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions Am Heart J 131 1097 1105 10.1016/S0002-8703(96)90083-6 1:STN:280: DyaK283isl2htQ%3D%3D 8644587 (Pubitemid 26176987)
8. J Davignon 2004 Beneficial cardiovascular pleiotropic effects of statins Circulation 109 III39 III43 15198965
9. V Pasceri G Patti A Nusca 2004 et al; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 110 674 678 10.1161/01.CIR. 0000137828.06205.87 1:CAS:528:DC%2BD2cXmtFOhu7g%3D 15277322 (Pubitemid 39056265)
10. G Patti V Pasceri G Colonna, et al. 2007 Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA ACS randomized trial J Am Coll Cardiol 49 1272 1278 10.1016/j.jacc.2007.02.025 1:CAS:528: DC%2BD2sXjslGktr0%3D 17394957 (Pubitemid 46467240)
11. G Di Sciascio G Patti V Pasceri, et al. 2009 Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial J Am Coll Cardiol 54 558 565 10.1016/j.jacc.2009.05.028 19643320
12. Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events (Naples) II Trial Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction. J Am Coll Cardiol. 2009 Aug 3.
13. WT Friedewald RI Levy DS Fredrickson 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 499 502 1:CAS:528:DyaE38Xkslagsbw%3D 4337382
14. RM Bell DM Yellon 2003 Atorvastatin, administrated at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway J Am Coll Cardiol 41 508 515 10.1016/S0735-1097(02)02816-4 1:CAS:528:DC%2BD3sXhvFCitbg%3D 12575984 (Pubitemid 36164511)
15. VA Mannacio D Iorio V De Amicis F Di Lello F Musumeci 2008 Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial J Thorac Cardiovasc Surg 136 1541 1548 10.1016/j.jtcvs.2008.06. 038 19114204
16. S Bellosta 1998 Direct vascular effects of HMG-CoA reductase inhibitors Atherosclerosis 137 S101 S109 10.1016/S0021-9150(97)00319-5 1:CAS:528: DyaK1cXivVClsr4%3D 9694549 (Pubitemid 28294215)
17. M Essig 1998 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins Circ Res 83 683 690 1:CAS:528: DyaK1cXmtlOgsrs%3D 9758637
18. S Colli 1997 Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis Arterioscler Thromb Vasc Biol 17 265 272 1:CAS:528:DyaK2sXhvFequ7c%3D 9081680
19. T Stalker A Lefer R Scalia 2001 A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti inflammatory effects on the microvascular endothelium: the role of mevalonic acid Br J Pharmacol 133 406 412 10.1038/sj.bjp.0704070 1:CAS:528:DC%2BD3MXktlSju7s%3D 11375257
20. V Laheta M Goicoechea S Garcia de Vinuesa, et al. 2007 Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins Curr Med Chem 14 243 248 10.2174/092986707779313381 (Pubitemid 46043919)
21. U Laufs V La Fata J Plutzky, et al. 1998 Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1129 1135 1:CAS:528:DyaK1cXisVWmsrY%3D 9537338
22. A Undas KE Brummel J Musial, et al. 2001 Simvastatin depresses blood clotting by inhibiting activation of prpthrombin, factor V, and factor XIII and by enhancing factor Va inactivation Circulation 103 2248 2253 1:CAS:528:DC%2BD3MXkt1Gnt7o%3D 11342472
23. P Meijer WJ Oyen D Dekker, et al. 2009 Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection Arterioscler Thromb Vasc Biol 29 963 968 10.1161/ATVBAHA.108.179622 1:CAS:528:DC%2BD1MXlslCnsLg%3D 19359665